Mark Crozier

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

Anderley Gordon, N. Finkler, Robert P. Edwards et al. · International Journal of Gynecological Cancer · 2005 · 221 citations

Medicine, Oncology, Pharmacology +17

Clear cell carcinoma of the ovary: A study of 59 cases

Mark Crozier, Larry J. Copeland, Elvio G. Silva et al. · Gynecologic Oncology · 1989 · 151 citations

Veterinary Medicine, Oncology, Pathology +11

Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Michael Teneriello, Paul C. Tseng, Mark Crozier et al. · Journal of Clinical Oncology · 2009 · 80 citations · Full text

Medicine, Oncology, Pharmacology +17

The modified radical vulvectomy with groin dissection: An eight-year experience

Matthew O. Burrell, Ernest W. Franklin, Michael J. Campion et al. · American Journal of Obstetrics and Gynecology · 1988 · 45 citations

Medicine, Gynecology, Surgery +10

Pelvic Exenteration for Adenocarcinoma of the Uterine Cervix

Mark Crozier, Mitchell Morris, Charles Levenback et al. · Gynecologic Oncology · 1995 · 21 citations

Medicine, Oncology, Surgery +9